drugset
drugset / Trial / NCT00131430

An Eighteen Month Efficacy and Safety Study in Obese Patients (0364-020)(COMPLETED)

NCT00131430 ↗

Phase 2/3 Completed 500 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

A study to determine the safety and efficacy of an investigational drug in patients with obesity.

Timeline

Start
2005-08
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject taranabant Unknown — —

Indications

obesity disorder